Incidence of thrombocytopenia with gemcitabine-based therapy and influence of dosing and schedule

Anti-Cancer Drugs

Volumn 12, Issue 4, 2001, Pages 383-385

  Cassidy, Catherine A ^a   Peterson, Patrick ^a   Cirera, Luis ^b   Roychowdhury, Debasish F ^a  

^a ELI LILLY AND COMPANY   (United States)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

21 versus 28 day schedule; Cisplatin dosing; Gemcitabine; Thrombocytopenia

Indexed keywords

GEMCITABINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMORBIDITY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HEMORRHAGE; HUMANS; INCIDENCE; PLATELET TRANSFUSION; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 0035000860     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200104000-00012     Document Type: Article

References (2)

1. 1. Conte PF, Bruzzone M, Carnino F, et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 1996; 14: 351-6.
2. 2. Gandara DR, Crowley J, Livingston RB, et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993; 11: 873-8.